INTRODUCTION
Hematopoietic stem cells (HSCs) are attractive targets for the cell and gene therapy of several inherited and acquired diseases. Because of self-renewing ability, multipotency and clonogenic potential, they can reconstitute all hematopoietic lineages in a transplanted host. Upon ex vivo gene transfer, they may generate a progeny of gene-corrected cells potentially for a life-span. For gene therapy to be efficacious, however, effective gene transfer must be reached into HSCs without inducing detrimental effects on their biological properties.
The vectors most often used for HSC gene transfer are gamma-retroviral vectors (RVs).
More recently, HIV-derived lentiviral vectors (LVs) have been proposed as improved tools for this task. Both RVs and LVs integrate into the genome of host cells, but, while RV integration is dependent on target cell mitosis, LVs transduce both proliferating and non-proliferating cells 1 .
Since HSCs are considered to be mostly quiescent cells, they require stimulation with cytokines that trigger them into the cell cycle, in order to be transduced by RVs. Consequently, all the protocols developed for RV-mediated HSC gene transfer involve prolonged ex vivo manipulation and/or induction of cell cycle entry and proliferation [2] [3] [4] [5] [6] , conditions that in most cases were shown to decrease the frequency of HSCs in the culture, and compromise their long term repopulating ability [6] [7] [8] [9] . Nevertheless, recent clinical trials have demonstrated that RVs can be successfully used for HSC-based SCID gene therapy [10] [11] [12] . However, the in vivo selective growth advantage of transduced cells, which enabled amplification of a small input of transduced HSCs, was a key factor in the success of these trials. To broaden significantly the scope of HSC-based gene therapy, preservation and transduction of the majority of HSCs harvested for a transplant would be required.
Others and we have shown efficient transduction of CB (CB) NOD/SCID mouseRepopulating Cells (SRCs), considered to be closely related to HSCs, after a short incubation with LV, in the absence of cytokine stimulation [13] [14] [15] . Surprisingly, and in apparent contrast with the lack of LV requirement for target cell proliferation, we later found a significant enhancement in gene transfer in the presence of a combination of early-acting cytokines (Interleukin 6 -IL6, Stem Cell only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From moderate ex vivo SRC expansion 17 . It remained to be established whether the gain in gene transfer could be offset, even for a short cytokine exposure, by a decreased engraftment or long-term repopulation capacity of the transduced cells. In order to address these issues in the SRC model, stringent experimental approaches are needed.
LVs have been shown to be restricted in quiescent T lymphocytes, which must exit from G 0 , and presumably progress to the G 1 b phase of the cell cycle, in order to be infected by HIV-1, or transduced by LVs [18] [19] [20] [21] . The transduction block in quiescent cells may be due to the lack of required cellular co-factors, and/or the expression of restrictive factors 22 . Several recent works have revealed that mammalian cells have developed defense mechanisms against retroviral infection (reviewed in Goff 23 ). Some of these factors may affect viral uncoating, reverse transcription, and/or target the internalized viral particles to degradation by the ubiquitin-proteasome pathway, whose antiviral activity was observed in earlier studies of HIV-infected lymphocytes 24 .
In this work, we assessed the impact of early-acting cytokines on HSCs in stringent models of NOD/SCID mouse repopulation, investigated factors limiting the efficiency of LV gene transfer in HSCs, and developed new strategies that may effectively overcome them.
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METHODS

Cells
HeLa, 293T and K562 cells were maintained in IMDM, U937 cells in RPMI-1640 (SIGMA), both containing 10% fetal bovine serum (FBS; Invitrogen). CD34+ cells were obtained from human CB, as described 16 , after informed consent according to the Declaration of Helsinki and the H. San
Raffaele Bioethical Committee, and used fresh or after freezing.
Transduction
Vector stocks were prepared, concentrated and tittered as described 25 HeLa or 293T/ml, 10 6 U937/ml, and 2x10 5 K562/ml were transduced for 12 hours with 5x10 4 , 2x10 5 and 5x10 5 LV TU/ml, respectively. Proteasome inhibitors MG132 (Calbiochem) and PS-341 (Millennium) were added to the transduction medium at the indicated concentration. Transduced cells were analysed by FACS (FACSCalibur) 6-14 days after transduction and by quantitative realtime PCR (qPCR) after 3 weeks; qPCR primers and probe complementary to the GFP or ψ vector sequences, and conditions were as described 17, 27 ; primers and probe complementary to the human TERT gene 28 were used to normalize DNA content. CFC assays were performed as described 16 , and colonies scored by light and fluorescence microscopy at day 10-14.
only. 17, 27 . LV copy numbers were normalized to human DNA content. Percentage of human only.
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S-phase suicide assay
After transduction with or without cytokines, 5x10 5 CD34+ cells/ml were exposed to 2x10 -6 M cytosine 1-β-D-arabinofuranoside (Ara-C; SIGMA) for 12 hours, or left untreated, then washed twice and plated in liquid culture and CFC assays. Killing efficiency was assessed by scoring CFC numbers.
Cell cycle analysis
CD34+ cells were incubated in DNA staining buffer (PBS 1% saponin with 300KU RNAse and 50 μg/ml PI), for 10 minutes in ice and then analyzed by FACS. Cell aggregates and dead cells were eliminated from further analysis by gating individual cells in the FL3-area versus FL3-width plot.
Proteasome assays
Cellular extracts were prepared as described 30 with minor modifications. Briefly, cells were sonicated in ice-cold buffer (50mM Tris/HCl pH 7.5, 1mM DTT, 0.25M sucrose, 5mM MgCl 2 , 0.5mM EDTA, 2mM ATP) and extracts were prepared by centrifugation. Peptidase activities were assayed by monitoring production of 7-amino-4-methylcoumarin (amc) from fluorogenic peptides, as described 31 . Suc-LLVY-amc (for chymotrypsin-like activity), Boc-LRR-amc (for trypsin-like activity) and Ac-YVAD-amc (for caspase-like activity) were used at 100 μM in 20 mM Tris-HCl Figure 3e , in order to make the differences in %GFP comparable across different doses, a logarithmic transformation was applied. A standard sign test was used for the data in Figure 5 . For the analysis of the Competitive Repopulation Assay see
Supplementary 
RESULTS
Cytokine stimulation preserved NOD/SCID repopulating ability of human HSCs
To stringently assess repopulation capacity of CB SRCs after a short ex vivo culture with and As shown in Table 1 , human cells engrafted mice at variable levels, as expected for the NOD/SCID model. The engraftment level was slightly lower in competitively than in noncompetitively repopulated mice (21% versus 35% CD45+ cells on average, respectively, n=20,20).
The frequency of transgene-expressing cells was on average higher for SRCs transduced with cytokines, in all permutations of vector type and experimental condition tested.
To assess whether cytokine stimulation had an impact on the repopulating capacity of the transduced SRCs we developed a statistical model (Supplementary Table 1 ). We confirmed that cytokines had a significant effect (p-value = 0.011) on the frequency of transgene-positive cells, with an estimated positive effect in the logodd scale equal to +1.044. This means that if the mean frequency of transduction is for example 30% for unstimulated cells (-cyt), the estimated mean frequency increases to 55% when stimulated (+cyt).
Because the interaction between the parameters "cytokines" and "xenotransplant model" (competitive or not) was not significant (p-value = 0.77), we concluded that cytokine stimulation had a positive significant impact on SRC transduction without changing significantly its extent and direction between reference and competitively repopulated mice, thus showing that cytokinestimulated SRCs had an engraftment capacity similar to that of unstimulated cells. We confirmed our findings at the vector DNA level, performing PCR analysis on DNA extracted from human colonies derived from engrafted mice BM (Supplementary Figure 1) .
Overall, these results showed that cytokine treatment, while increasing LV transduction of human HSCs, did not affect their engraftment and repopulating ability in a stringent xenotransplant model.
Cytokine enhancement of SRC gene transfer does not require cell cycle progression
A possible explanation for the cytokine enhancement of LV transduction was that only the SRCs in the G 1 phase of the cell cycle were susceptible to transduction, and that cytokines enhanced transduction triggering the exit of SRCs from G 0 . Progression into late G 1 , however, commits the cells to DNA replication and mitosis, and may thus impair the long-term repopulating ability of HSCs, a difficult feature to assess in the NOD/SCID model. Since we could not measure the cell cycle status of the few SRCs contained in the CD34+ population, we performed an S-phase suicide assay on the transduced cells. We stimulated or not CB-derived CD34+ cells with cytokines, and then exposed the cells or not to 1-β-D-arabinofuranoside (Ara-C) to kill cycling cells. Ara-C was previously reported to effectively kill hematopoietic stem/progenitor cells (HSPCs) passing through S-phase [34] [35] [36] [37] . To verify the cell cycle status of the cells after treatment, we stained them with propidium iodide and analyzed by FACS (Figure 2a) . Cytokines increased the fraction of cells in S-phase (17% for +cyt vs 9% for -cyt) and this difference was completely abrogated when the cells were exposed to Ara-C.
We then transduced CD34+ cells with LV-GFP, exposed them or not to Ara-C, performed in vitro assays, and injected the cells into NOD/SCID mice. CFC assay showed that Ara-C killed the majority of cytokine-stimulated cells and a much smaller fraction of non-stimulated cells, indicating that cytokines triggered committed progenitors into S-phase, as expected. Nevertheless, when scoring transduction frequency in the surviving cultures, both suspension cultures and CFCs, we did not observed a decrease in transduction levels in the cells exposed to Ara-C (Figure 2b ,c). We obtained similar results using 3 H-Thymidine as killing agent (not shown).
For transplantation, transduced cells were matched for number of viable cells prior to Ara-C treatment, and injected with CD34 Neg accessory cells. NOD/SCID BM cells were harvested 6-8 weeks after transplant, analyzed by FACS and plated for CFC assay (Table 2) . FACS analysis showed, for the cells not exposed to Ara-C, a higher SRCs transduction level when cytokines were added (91% vs 54% for +cyt vs -cyt). Interestingly, we observed a similarly significant difference in the cells exposed to Ara-C (61% vs 29% for +cyt Ara-C and -cyt Ara-C, respectively). CFC assay confirmed these data.
Since cytokine enhancement of SRC transduction was not abrogated by killing proliferating cells, it did not require progression into the S-phase of the cell cycle. Ara-C treatment decreased engraftment and transduction levels in both stimulated and non-stimulated SRCs, indicating that a fraction of SRCs were sensitive to Ara-C, most likely because they were induced to proliferate early after transplant. One can thus postulate that the quiescent SRC fraction was mainly responsible for only.
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Lentiviral gene transfer is restricted by proteasome in HSPCs
We showed that cytokines enhancement of LV gene transfer was not dependent on the envelope pseudotype ( Supplementary Figure 2) , indicating that cytokine stimulation did not affect a specific entry pathway. Thus, we evaluated factors influencing the post-entry steps of viral infection. For Overall, these data indicated that the proteasome effectively restricted LV gene transfer in
HSPCs.
Cytokines down-regulate the proteasome activity of HSPCs
We assessed the contribution of individual cytokines to the observed enhancement of LV transduction by taking advantage of the response amplification mediated by MG132. We transduced 
cytokines on gene transfer appeared to be synergistic, as indicated by the frequency of transduction, which reached saturation at 100%, and by the transduced cells MFI.
We then assayed the proteasomal chymotriptic-, tryptic-and caspase-like activities in CD34+ cells stimulated or not with cytokines. We found that, for all activities tested, cytokinestimulated CD34+ cells displayed a significantly lower specific activity, on average 60%, compared to not stimulated cells (global p-value= 2x2 -18 ) (Figure 5a) . We then performed a time-course analysis of the chymotriptic-like proteasome activity, which accounts for 90% of the total activity of this complex, of CD34+ cells stimulated or not with cytokines (Figure 5b ). Whereas the proteasome activity progressively increased in cultured unstimulated CD34+ cells, it was rapidly and strongly down-regulated by exposure to cytokines. Indeed, the difference in specific activity between stimulated and not stimulated cells was higher at 6 hrs (earliest time analyzed; 30% of unstimulated cells) than at 24 hours.
Since we observed an additive effect of cytokines and proteasome inhibitor in enhancing transduction (see Fig. 3 and 4) , we measured the proteasome activity 24 hours after either treatment, or their combination (Figure 5c ). MG132 down-regulated the proteasome activity more effectively than the cytokines, and the combination was slightly but not significantly more effective than the drug alone.
Finally, we assessed the contribution of each individual cytokine (Figure 5d ). We observed a moderate down-regulation of proteasome activity when CD34+ cells were exposed to SCF, TPO or Flt3L, while no effect was seen with IL6. No cytokine tested alone reached the effect of the cocktail, indicating an additive effect of three cytokines.
Overall, the rapid onset and the substantial extent of proteasome activity down-regulation induced by cytokines in HSPCs indicate a likely role of this response in mediating the enhancement of LV transduction. However, because the addition of cytokines to cells exposed to proteasome inhibitor further enhanced transduction without likely inducing a comparatively stronger only.
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Proteasome restriction of LV appears to be a specific feature of HSPCs
In order to verify if proteasome restriction of LVs was common to different cell types, we evaluated the effect of MG132 on the transduction of different cell lines, either of hematopoietic origin (K562 and U937) or not (293T and HeLa). Cells were transduced with a constant LV-GFP dose and with increasing MG132 doses, washed and analyzed two weeks later by FACS. The effect of MG132 on transduction was much lower for all the cell lines tested than that observed in HSPCs (Figure 6a These results suggest that proteasome restriction of LV is a specific feature of HSPCs and that it could be due to the high proteasome activity observed in these cells.
Proteasome inhibition strongly enhances SRC gene transfer by LV
We then verified the effect of proteasome inhibition on SRC transduction. We transduced CD34+ Our marking studies provides rigorous, and until now lacking, proof that early-acting cytokines, which are currently investigated for ex vivo HSC expansion, do not impair stem cell properties in the conditions tested. Previous studies reported a decreased homing capacity of CB CFCs after exposure to some of the cytokines used in this study 40 . Although our results do not suggest such impairment, we cannot exclude that cytokine-stimulated cells may compensate a decreased homing capacity with a higher in vivo self-renewal and/or clonogenicity. Clonal analysis of the human graft in the repopulated mice will help clarifying these issues. On the other hand, because the SRC assay does not provide extended long-term follow-up and does not support Tlymphopoiesis, we cannot exclude detrimental effects of the cytokines on these more-difficult-toassess stem cell features. Further studies in new xenograft models [41] [42] [43] [44] , or, more likely, the followup of patients treated with LV-mediated HSC gene therapy will address these issues.
Our studies indicate that, according to the absence or presence of cytokines, HSC gene transfer can be tuned to limit the average level of vector integration, and reduce the risk of insertional mutagenesis, or instead to maximize transduction and transgene expression levels.
Because LV integration preferentially targets active genes, cytokine stimulation may also affect the integration sites spectrum, making less or more likely that cytokine-responsive, growth-related genes are targeted.
Cytokines enhancement of SRC transduction was not linked to cell progression into S-phase, because it was not abrogated by treating the cells with the S-phase poison Ara-C after transduction.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From statistically significant, levels of human engraftment and transduction in transplanted mice. This suggests that a fraction of SRCs may become sensitive to Ara-C in vivo and that cells in this fraction are more permissive to LV. These more permissive cells may be those exiting from quiescence; because of an earlier S-phase induction upon transplantation, they may become sensitive to the delayed effect of Ara-C in vivo. The cells less susceptible to LV may be the quiescent cells; because of a delayed S-phase induction upon transplantation, they may be resistant to Ara-C. Because the SRCs successfully engrafting after Ara-C treatment were transduced to substantial levels, these findings strongly suggest that LVs are able to transduce quiescent SRCs. In this respect, HSCs may behave differently than lymphocytes that restrict LV transduction, and HIV-1 infection, in the G 0 phase of the cell cycle.
In recent studies, restriction of retroviral and lentiviral infection has been ascribed to different families of cytosolic proteins that target viral uncoating or edit the viral genome and inhibit viral replication (reviewed in Goff
23
). Factors interfering with viral uncoating, such as TRIM5α, are typically identified by saturating their activity with increasing viral input. We could not overcome the relative resistance of unstimulated, as compared to cytokine-stimulated, cells by increasing the vector input. Rather than being dependent on cell cycle progression, or the elimination of a cytosolic restriction factor, the enhancement of LV transduction by cytokines in HSPCs may involve, at least in part, down-regulation of the proteasome activity. By directly testing the proteasome activities in stimulated and unstimulated HSPCs, we showed that they were significantly down-regulated by exposure to the cytokines. Importantly, this cytokines response was rapid, with a maximal effect at early time points corresponding to the period in which the first steps of LV transduction take place. Although it is difficult to estimate the actual level of inhibition reached in cells treated with MG132, the activity recovered after 24 hour exposure was similar to that recovered from cells exposed for 6 hours to cytokines, suggesting that the extent of downregulation induced by the latter was substantial. However, because cytokine treatment further Since we obtained a very high vector copy number in SRCs transduced with cytokines and proteasome inhibitor, further studies are needed to assess the impact on the target cell genome and evaluate the possible consequences of the increased insertional mutagenesis. However, as shown in Figure 3 , using proteasome inhibitors in absence of cytokine stimulation allows reaching highfrequency transduction without necessarily increasing the average vector copy number to extremely high levels, thus providing a possible new strategy to optimize gene transfer. It is conceivable that both minimal and maximal thresholds of vector copy numbers providing the best risk-benefit ratio will have to be set according to each proposed gene therapy application.
Whereas proteasome inhibition increased LV transduction to some extent in several cell lines, effective proteasome restriction appeared to be a specific feature of HSPCs (this study) and lymphocytes 24 . We correlated effective restriction with the high proteasome activity observed in only.
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In conclusion, we report a substantial increase in SRC gene transfer in the presence of proteasome inhibitor, and, importantly, no apparent adverse effect on the cell engraftment capacity.
Further studies will determine the safety and efficacy of this approach to improve HSC gene therapy.
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